Sharemaestro Newsreel

Will Hims & Hers’ Higher 2026 Revenue Guidance Amid Rising Losses Change HIMS’s Investment Narrative?

Hims & Hers Health, Inc. reported second-quarter 2026 sales of US$753.21 million, up from US$544.83 million a year earlier, but moved from net income of US$42.51 million to a net loss of US$86.29 million, while also raising full-year 2026 revenue guidance to between US$3.10 …

Globus Medical (GMED) Upgraded to Strong Buy: Here's Why

Globus Medical (GMED) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The …

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

Hims & Hers stock trims losses following quarterly results

What happened: Hims & Hers Health (HIMS) stock declined 3% before trimming losses on Tuesday. What's behind the move: Shares were volatile after the telehealth company swung to a loss of $0.37 per share in the second quarter from a profit of $0.17 a …

GMED vs. ITGR: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods …

Hims & Hers Q2 revenue beat offset by wider-than-expected loss

Hims & Hers Q2 revenue beat offset by wider-than-expected loss Proactive uses images sourced from Shutterstock Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the …

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

RadNet, Inc. RDNT reported second-quarter 2026 adjusted earnings of 29 cents per share, down 14.7% year over year but ahead of the Zacks Consensus Estimate of 18 cents by 61.1%. GAAP EPS was 10 cents compared with 19 cents in the prior-year period. Growth …

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak Sciences KOD announced that it initiated a global late-stage ALTO study evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational bispecific therapy that targets IL-6 and VEGF for the treatment of retinal vascular diseases. Patient enrollment is ongoing. DME …

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...

This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up …

Apertura EE. UU.: Nasdaq busca dirección 🗽 Las acciones de Hims & Hers reaccionan a los resultados

The Zacks Analyst Blog Highlights Illumina, Qnity Electronics and nVent Electric

For Immediate Release Chicago, IL – August 11, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026, at 9:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and Chair of the Management Board - Helen Giza Chief Financial Officer - Martin Fischer Investor Relations - Dominik Heger Full Conference Call Transcript Operator: …

Pronóstico semanal de las acciones de Johnson & Johnson: El impulso se mantiene con MACD alcista y volatilidad estable

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

CVS Health Earns Two Gold and One Silver Stevie(R) Awards for Great Employers

AI Learning Academy honored for building enterprise-wide AI literacy and colleague confidence WOONSOCKET, RI / ACCESS Newswire / August 11, 2026 / Originally published on CVS Health Company Newsroom CVS Health® (NYSE:CVS) announced that its AI Learning Academy earned two Golds and one Silver …

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is …

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as …

These stocks have some of Wall Street’s lowest short interest

[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares …

Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves

Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF …

GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average

GE HealthCare Technologies (GEHC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GEHC broke through the 200-day moving average, which suggests a long-term bullish trend. The 200-day simple moving average helps traders and analysts …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results

S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a …

Hims & Hers Health Stock Slides 6% After Rising Expenses Trigger Q2 Net Loss

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run

Quick Read ISRG is down 31% YTD, but its razor-and-razorblade model now delivers 85% recurring revenue across a fleet of 11,710 da Vinci systems. MDT's Hugo and JNJ's Ottava remain early or pre-commercial, leaving ISRG's $1.73 billion quarterly instruments-and-accessories stream with no real soft-tissue …

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced …

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future …

Hims & Hers' Revenue Growth Comes at a Cost

This article first appeared on GuruFocus. Hims & Hers Health, Inc. (NYSE:HIMS) fell 6.11% in premarket after reporting second-quarter revenue of $753.2 million, up 38% year over year and above the $699 million analysts estimate. The company added 452,000 subscribers during the past year, …

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

Hims & Hers Raises Outlook as Cash Flow Weakens

This article first appeared on GuruFocus. Hims & Hers Health Inc. (HIMS, Financials) the digital health platform, boosted its full-year revenue outlook after another quarter of robust growth, but investors are also getting a better sense of what that expansion will cost. Warning! GuruFocus …

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson’s Precision Medicine

Olink™ Explore HT analysis of approximately 5,500 research samples completed, with data now available Key Facts Collaboration: Thermo Fisher Scientific and The Michael J. Fox Foundation expanded the Parkinson's Precision Medicine Initiative (PPMI) proteomic data resource. Scale: Approximately 5,500 research samples were analyzed using …